Assembly Biosciences (ASMB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$74.8M

Revenue (quarter)

$13.4M

Revenue growth (year over year)

+38.94%

Gross profit (trailing twelve months)

$74.8M

Gross margin

100.00%

Net income (trailing twelve months)

−$42,000.00

Net income (quarter)

−$3.9M

Net income growth (year over year)

+62.18%

Net margin

−0.06%

Return on equity

−0.03%

EPS (trailing twelve months)

$1.24

Book value per share

$15.40

P/E (trailing twelve months)

—

Price to book

1.37

Debt to assets

7.61%

Payout ratio

—

Dividend yield

—

Company profile

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

• Is Assembly Biosciences (ASMB) profitable?

  No. Assembly Biosciences reported a net loss of $42,000.00 over the trailing twelve months.

• How much revenue does Assembly Biosciences (ASMB) make?

  Assembly Biosciences generated $74.8M in revenue over the trailing twelve months, up 38.94% year over year.

• How do I buy stock in Assembly Biosciences (ASMB)?

  ASMB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.